Docoh
Loading...

107 results

Filter options loading...
Top filers
Top filing types
Recent filing years
10-Q
2021 Q2
ANIX Anixa Biosciences Inc
10 Jun 21
Quarterly report
4:30pm
We follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in five reportable segments, each with different operating and potential revenue generating characteristics: (i) CAR-T Therapeutics, (ii) Cancer Vaccines, (iii) Anti-Viral Therapeutics, (iv) Cancer Diagnostics and (v) Patent Licensing activities. The following represents selected financial information for our segments for the three and six months ended April 30, 2021 and 2020 and as of April 30, 2021 and October 31, 2020:
For the Three Months Ended April 30,For the Six Months Ended April 30,
2021202020212020
Net Income/(Loss):
CAR-T Therapeutics$(1,445,758)$(495,030)$(2,406,494)$(1,125,363)
Cancer Vaccines(662,367)(170,271)(1,568,703)(365,867)
Anti-Viral Therapeutics(309,755)(309,504)(790,561)(309,504)
Cancer Diagnostics(13,409)(1,679,027)(22,371)(3,469,673)
Patent Licensing(5,600)(4,158)118,863(4,158))
Total$(2,436,889)$(2,657,990)$(4,669,266)$(5,274,565)
Total operating costs and expenses$2,437,282$2,670,137$5,182,913$5,300,006
Less non-cash share-based compensation(1,051,272)(1,110,086))(2,037,371)(2,131,420)
Operating costs and expenses excluding non-cash share-based compensation$1,386,010$1,560,051$3,145,542$3,168,586
Operating costs and expenses excluding non-cash share based compensation:
CAR-T Therapeutics$934,714$223,822$1,492,394$570,163
Cancer Vaccines298,53767,059836,525165,329
Anti-Viral Therapeutics138,175221,018408,431221,018
Cancer Diagnostics10,2911,044,88916,7232,208,813
Patent Licensing4,2933,263391,4693,263
Total$1,386,010$1,560,0513,145,542$3,168,586
10-Q
2021 Q2
ANIX Anixa Biosciences Inc
10 Jun 21
Quarterly report
4:30pm
April 30, 2021October 31, 2020
Total assets:
CAR-T Therapeutics$25,906,018$2,988,124
Cancer Vaccines8,265,734946,923
Anti-Viral Therapeutics3,825,8762,464,361
Cancer Diagnostics332,4502,869,529
Patent Licensing167,444184,027
Total$38,497,522$9,452,964
10-Q
2021 Q1
PFE Pfizer Inc.
13 May 21
Quarterly report
11:32am
The following provides detailed revenue information for several of our major products:
(MILLIONS)Three Months Ended
PRODUCTPRIMARY INDICATION OR CLASSApril 4, 2021March 29, 2020
TOTAL REVENUES(a)$14,582$10,083
Vaccines$4,894$1,611
BNT162b2 alliance revenues and direct salesActive immunization to prevent COVID-193,4620
Prevnar 13/Prevenar 13Pneumococcal disease1,2841,450
FSME/IMMUN-TicoVacTick-borne encephalitis disease5348
NimenrixMeningococcal disease4675
All other VaccinesVarious4938
Oncology$2,862$2,435
IbranceHR-positive/HER2-negative metastatic breast cancer1,2541,248
Xtandi alliance revenuesmCRPC, nmCRPC, mCSPC267209
InlytaAdvanced RCC229169
SutentAdvanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor200205
XalkoriALK-positive and ROS1-positive advanced NSCLC134149
BosulifPhiladelphia chromosome–positive chronic myelogenous leukemia123100
Retacrit(b)Anemia10989
Ruxience(b)Non-hodgkin’s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener’s Granulomatosis) and microscopic polyangiitis987
Zirabev(b)Treatment of mCRC; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic RCC; and persistent, recurrent or metastatic cervical cancer866
LorbrenaALK-positive metastatic NSCLC6042
AromasinPost-menopausal early and advanced breast cancer5234
BesponsaRelapsed or refractory B-cell acute lymphoblastic leukemia5044
BraftoviIn combination with Mektovi for metastatic melanoma in patients with a BRAFV600E/K mutation and, in combination with Erbitux® (cetuximab), for the treatment of BRAFV600E-mutant mCRC after prior therapy4737
MektoviIn combination with Braftovi for metastatic melanoma in patients with a BRAFV600E/K mutation3537
All other OncologyVarious11959
Internal Medicine$2,594$2,332
Eliquis alliance revenues and direct salesNonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism1,6431,300
Chantix/ChampixAn aid to smoking cessation treatment in adults 18 years of age or older217270
Premarin familySymptoms of menopause143152
PristiqDepression6041
ToviazOveractive bladder5760
All other Internal MedicineVarious474509
Hospital(a)$2,343$2,088
SulperazonBacterial infections192187
MedrolAnti-inflammatory glucocorticoid99129
ZaviceftaBacterial infections9449
ZithromaxBacterial infections89138
VfendFungal infections8074
FragminTreatment/prevention of venous thromboembolism7159
EpiPenEpinephrine injection used in treatment of life-threatening allergic reactions6684
ZyvoxBacterial infections5570
PrecedexSedation agent in surgery or intensive care5542
IVIg Products(c)Various10598
Pfizer CentreOne(d)Various391152
All other Anti-infectivesVarious397395
All other HospitalVarious648610
Inflammation & Immunology (I&I)$1,065$978
XeljanzRA, PsA, UC, active polyarticular course juvenile idiopathic arthritis538451
Enbrel (Outside the U.S. and Canada)RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis319347
10-Q
2021 Q1
MRNA Moderna Inc
6 May 21
Quarterly report
4:30pm
Three Months Ended March 31,
20212020
Program expenses by modality:
Prophylactic vaccines$248$9
Cancer vaccines174
Intratumoral immuno-oncology62
Systemic secreted and cell surface therapeutics11
Systemic intracellular therapeutics57
Total program-specific expenses by modality (1)27723
Other research and development expenses:
Discovery programs1310
Platform research2522
Technical development and unallocated manufacturing expenses3329
Shared discovery and development expenses3919
Stock-based compensation1412
Total research and development expenses$401$115
10-Q
2021 Q1
ANIX Anixa Biosciences Inc
11 Mar 21
Quarterly report
4:30pm
We follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in five reportable segments, each with different operating and potential revenue generating characteristics: (i) CAR-T Therapeutics, (ii) Cancer Vaccines, (iii) Anti-Viral Therapeutics, (iv) Cancer Diagnostics and (v) our legacy Patent Licensing activities. The following represents selected financial information for our segments for the three months ended January 31, 2021 and 2020 and as of January 31, 2021 and October 31, 2020:
For the Three Months Ended January 31,
20212020
Net loss:
CAR-T Therapeutics$(960,736)$(630,333)
Cancer Vaccines(906,336)(195,596)
Anti-Viral Therapeutics(480,806)-
Cancer Diagnostics(8,962)(1,790,646)
Patent Licensing124,463-
Total$(2,232,377)$(2,616,575)
Total operating costs and expenses$2,745,631$2,629,869
Less non-cash share-based compensation(986,099)(1,021,334)
Operating costs and expenses excluding non-cash share-based compensation$1,759,532$1,608,535
Operating costs and expenses excluding non-cash share based compensation expense:
CAR-T Therapeutics$557,680$346,341
Cancer Vaccines537,98898,270
Anti-Viral Therapeutics270,256-
Cancer Diagnostics6,4321,163,924
Patent Licensing387,176-
Total$1,759,532$1,608,535
10-Q
pd9mk 1jjjv7lv
11 Mar 21
Quarterly report
4:30pm
10-K
4fe6lk
25 Feb 21
Annual report
7:00pm
10-K
sk696i
7 Jan 21
Annual report
4:15pm
10-K
b4cgc0a0409hnpi2
7 Jan 21
Annual report
4:15pm
10-Q
qs29c2wwcvd 09emcr
30 Oct 20
Quarterly report
8:24am
10-Q
2uqhow7
8 Sep 20
Quarterly report
4:30pm
10-Q
5omb a8i9td7i0
8 Sep 20
Quarterly report
4:30pm
10-Q
6v0vndsydrn7a
6 Aug 20
Quarterly report
4:28pm
10-Q
mh91s2zcjrum
9 Jun 20
Quarterly report
5:11pm
10-Q
37o2zttxnw8t
9 Jun 20
Quarterly report
5:11pm
10-Q
ewcfew
7 May 20
Quarterly report
4:03pm
10-Q
ye7foh chr
7 May 20
Quarterly report
10:42am
10-K
86peu kw6
27 Feb 20
Annual report
4:33pm
10-Q
tf91wr 22aw8n0syz16
7 Nov 19
Quarterly report
3:55pm
10-Q
4ihqf2vkabp2mgpinwy9
6 Nov 19
Quarterly report
4:01pm